Buscopan analgesic solution, 100 ml
Description
Antispasmodic. Solution.
Buscopan (combination of scopolamine and metamizole)
Composition:
- N-butylscopolamine bromide (active substance): 4.00 mg
- Metamizole sodium (active substance): 500.00 mg
- Phenol (preservative): 5 mg
Pharmacological properties:
Buscopan® contains the antispasmodic N-butylscopolamine bromide and nonsteroidal anti-inflammatory drugs.
Metamizole (NSAIDs). Buscopan® has an antispasmodic effect on the gastrointestinal tract and genitourinary system.
N-butylscopolamine bromide is a Quaternary ammonium derivative of scopolamine. This compound is an antagonist of acetylcholine activity at M-cholinoreceptors, and also has some activity at nicotinic receptors. Its pharmacological properties are similar to the main representative of this class of drugs, atropine (such as antispasmodic properties, increased heart rate, suppression of salivary and lacrimal secretion). After parenteral administration, N-butylscopolamine bromide is mainly excreted in the urine (about 54%).
Metamizole has anti-inflammatory, analgesic and antipyretic effects. The mechanism of its action, like other NSAIDs, is associated with suppression of prostaglandin synthesis. It is also an antagonist of bradykinin and histamine.
After intravenous administration, excretion occurs mainly in the urine (50 – 70% depending on the species).
Indication:
Buscopan® is indicated in the treatment of abdominal pain associated with spastic colic. Buscopan® does not mask the symptoms in the case of surgical colic and does not cause intestinal paralysis.
Buscopan® is used in the treatment of calf diarrhea, it reduces pain and normalizes intestinal function by reducing peristalsis.
Doses and methods of administration:
Buscopan is administered in a single dose of 0.2 mg of N-butylscopolamine bromide and 25 mg of metamizole / kg body weight. This corresponds to 5 ml of solution for injection / 100 kg of body weight intravenously. After intravenous injection of Buscopan, the antispasmodic effect occurs 2-5 minutes after administration and lasts for 4-6 hours. A single injection is usually sufficient to achieve a significant improvement and reduce spasm and pain. If necessary, Buscopan can be re-introduced after 4-6 hours.
Calves Buscopan is administered at a dose of 0.4 mg of N-butylscopolamine bromide and 50 mg of metamizole / kg body weight at 12-hour intervals for a maximum of three days by intravenous or intramuscular injection. A single dose corresponds to 1 ml of solution for injection / 10 kg of body weight intravenously.
*Kilograms to Pounds conversion table
Kilograms (kg) | Pounds (lb) | Pounds+Ounces (lb+oz) |
0.1 kg | 0.220 lb | 0 lb 3.527 oz |
1 kg | 2.205 lb | 2 lb 3.274 oz |
5 kg | 11.023 lb | 11 lb 0.370 oz |
10 kg | 22.046 lb | 22 lb 0.740 oz |
Overdose:
The toxicity of both components is very low. The toxicity study in rats revealed non-specific symptoms such as ataxia, mydriasis, tachycardia, prostration, convulsions, coma and respiratory symptoms.
Antidotes: Physostigmine for N-butylscopolamine bromide. There are no specific antidotes for metamizole. In case of overdose, symptomatic therapy is required.
Contraindication:
Hypersensitivity, arrhythmias, heart failure, portal stenosis, glaucoma, nonspecific ulcerative colitis.
Side effects:
In horses, there may be a slight and short-term increase in heart rate due to the parasympathetic activity of N-butylscopolamine bromide.
Special precautions:
Missing
Use during pregnancy and lactation:
Laboratory studies in rats and rabbits showed no obvious teratogenic effects. The drug can be used during pregnancy in regular doses.
Interaction with other medicinal products:
The effect of N-butylscopolamine bromide or metamizole may be potentiated by the concomitant use of other anticholinergic and analgesic agents. Although specific interactions are not described, the introduction of other anticholinergic drugs is contraindicated.
Packing form:
Buscopan® is available in amber glass vials containing 100 ml of solution for injection. Each vial is packed in a cardboard box.
Storage conditions:
Store below 30 ° C.
Expiration date:
Unused vial: 4 years.
After first use: 6 months.